Rocket Pharmaceuticals (STU:9IP1) Ending Cash Position : €157.57 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Ending Cash Position?

Rocket Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 was €157.57 Mil.

Rocket Pharmaceuticals's quarterly Ending Cash Position increased from Jun. 2024 (€37.13 Mil) to Sep. 2024 (€60.33 Mil) and increased from Sep. 2024 (€60.33 Mil) to Dec. 2024 (€157.57 Mil).

Rocket Pharmaceuticals's annual Ending Cash Position declined from Dec. 2022 (€133.91 Mil) to Dec. 2023 (€52.52 Mil) but then increased from Dec. 2023 (€52.52 Mil) to Dec. 2024 (€157.57 Mil).

Rocket Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Rocket Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Ending Cash Position Chart

Rocket Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

245.50

207.12

133.91

52.52

157.57

Rocket Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															52.52	33.71	37.13	60.33	157.57

Rocket Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Rocket Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	54.698	+	102.874
	=	157.57

Rocket Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	63.948	+	93.624
	=	157.57

Rocket Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Rocket Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (STU:9IP1) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

RCKT:USA

Address

9 Cedarbrook Drive, Cranbury, NJ, USA, 08512

Website

https://www.rocketpharma.com

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals Headlines

No Headlines